AFT Pharmaceuticals - Big win with Maxigesic Rapid’s FDA nod
AFT Pharmaceuticals (AFT) has announced it has received FDA approval for Maxigesic Rapid tablets, a quick-release version of its flagship Maxigesic...
154 Views
AFT Pharmaceuticals - Portfolio expansion with new in-licensing deal
AFT Pharmaceuticals continues to strengthen its R&D pipeline with the announced in-licensing agreement with Latitude Pharmaceuticals (a...
235 Views
AFT Pharmaceuticals - Maxigesic IV expands into East European markets
AFT Pharmaceuticals has announced an exclusive licensing and distribution agreement for the Maxigesic intravenous (IV) formulation with Salus...
227 Views
AFT Pharmaceuticals - Progressive outlook for CY23
AFT Pharmaceuticals has presented its key CY22 highlights and strategic priorities for CY23 in a letter to investors. In addition to new product...
425 Views
AFT Pharmaceuticals - H123 focused on portfolio expansion
AFT reported strong post COVID-19 revenue momentum in H123 (NZ$65.8m, 18.4% y-o-y growth), driven by robust organic growth across all regions,...
663 Views